[
  {
    "ts": null,
    "headline": "Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk",
    "summary": "U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy.  Metsera, based in New York, has no products on the market, but it is developing oral and injectable treatments.  The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity.",
    "url": "https://finnhub.io/api/news?id=f123a4fc980c82df899bd39fd99c37290dbbef05407f6b39797a36a95c41d2bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762623252,
      "headline": "Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk",
      "id": 137384603,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy.  Metsera, based in New York, has no products on the market, but it is developing oral and injectable treatments.  The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity.",
      "url": "https://finnhub.io/api/news?id=f123a4fc980c82df899bd39fd99c37290dbbef05407f6b39797a36a95c41d2bc"
    }
  },
  {
    "ts": null,
    "headline": "2 No-Brainer Dividend Stocks to Buy With $100 in November",
    "summary": "There's no need to break the bank to get your hands on excellent dividend payers.",
    "url": "https://finnhub.io/api/news?id=c65e2f9049ab9304904429fd8de49f425b0e7075e4b0df3fb18b99158e26d664",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762611300,
      "headline": "2 No-Brainer Dividend Stocks to Buy With $100 in November",
      "id": 137384570,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "There's no need to break the bank to get your hands on excellent dividend payers.",
      "url": "https://finnhub.io/api/news?id=c65e2f9049ab9304904429fd8de49f425b0e7075e4b0df3fb18b99158e26d664"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer wins $10 billion Metsera bidding war as Novo Nordisk exits",
    "summary": "STORY: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera.It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday (November 8) it would exit the race. Metsera accepted a sweetened offer from Pfizer late Friday (November 7). It cited U.S. antitrust risks in Novo's bid that it had previously called superior. Novo said in a statement that it believed its offer structure was \"compliant with antitrust laws.\"Metsera’s drugs are projected to reach $5 billion in peak sales.And this win hands Pfizer a way into the lucrative obesity drug market - even if Metsera’s treatments remain years away from hitting shelves. It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.The Danish drugmaker later said it’s advancing its own pipeline of treatment options for obesity…And that it would \"continue to assess opportunities for business development and acquisitions”.Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.",
    "url": "https://finnhub.io/api/news?id=74f4c9d163e2748e85a30cc4a3a272dff743993d2f722a0ac1c45e9bcb965784",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762607874,
      "headline": "Pfizer wins $10 billion Metsera bidding war as Novo Nordisk exits",
      "id": 137384528,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "STORY: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera.It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday (November 8) it would exit the race. Metsera accepted a sweetened offer from Pfizer late Friday (November 7). It cited U.S. antitrust risks in Novo's bid that it had previously called superior. Novo said in a statement that it believed its offer structure was \"compliant with antitrust laws.\"Metsera’s drugs are projected to reach $5 billion in peak sales.And this win hands Pfizer a way into the lucrative obesity drug market - even if Metsera’s treatments remain years away from hitting shelves. It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.The Danish drugmaker later said it’s advancing its own pipeline of treatment options for obesity…And that it would \"continue to assess opportunities for business development and acquisitions”.Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.",
      "url": "https://finnhub.io/api/news?id=74f4c9d163e2748e85a30cc4a3a272dff743993d2f722a0ac1c45e9bcb965784"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer poised to buy Metsera in USD10 billion deal after bidding war",
    "summary": "Pfizer poised to buy Metsera in USD10 billion deal after bidding war",
    "url": "https://finnhub.io/api/news?id=54d323437036fabc5253166d0a5eaa23eb303038ed58fa86b7353ec515a179f8",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762607635,
      "headline": "Pfizer poised to buy Metsera in USD10 billion deal after bidding war",
      "id": 137378782,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=54d323437036fabc5253166d0a5eaa23eb303038ed58fa86b7353ec515a179f8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer wins bidding war for Metsera with $10B offer",
    "summary": "The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.",
    "url": "https://finnhub.io/api/news?id=c5a8a12d8f554df70f2b958ca2fa65a1a55df6498c7339eda686f70a4f7b353f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762602960,
      "headline": "Pfizer wins bidding war for Metsera with $10B offer",
      "id": 137384606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.",
      "url": "https://finnhub.io/api/news?id=c5a8a12d8f554df70f2b958ca2fa65a1a55df6498c7339eda686f70a4f7b353f"
    }
  },
  {
    "ts": null,
    "headline": "Metsera (MTSR) Hits New High on Billion-Dollar Bidding War",
    "summary": "We recently published 10 Stocks on Fire Amid Market Chaos. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera soared to a new all-time high on Thursday as buying appetite was bolstered by an intensifying billion-dollar bidding war from two pharmaceutical giants. At intra-day trading, Metsera, Inc. (NASDAQ:MTSR) climbed to a new […]",
    "url": "https://finnhub.io/api/news?id=6b5026f2e544762012390ddca9b4814f3793bd2adf5de7d2791f47c98e5d4f2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762596778,
      "headline": "Metsera (MTSR) Hits New High on Billion-Dollar Bidding War",
      "id": 137378430,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks on Fire Amid Market Chaos. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera soared to a new all-time high on Thursday as buying appetite was bolstered by an intensifying billion-dollar bidding war from two pharmaceutical giants. At intra-day trading, Metsera, Inc. (NASDAQ:MTSR) climbed to a new […]",
      "url": "https://finnhub.io/api/news?id=6b5026f2e544762012390ddca9b4814f3793bd2adf5de7d2791f47c98e5d4f2a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer wins $10 billion bidding war for weight-loss start-up Metsera",
    "summary": "Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after Ozempic maker Novo...",
    "url": "https://finnhub.io/api/news?id=b4e397ba918c0f497879e9de820cad35a0ae0a72f904b245a58d829602f14a77",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762593472,
      "headline": "Pfizer wins $10 billion bidding war for weight-loss start-up Metsera",
      "id": 137378431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after Ozempic maker Novo...",
      "url": "https://finnhub.io/api/news?id=b4e397ba918c0f497879e9de820cad35a0ae0a72f904b245a58d829602f14a77"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer",
    "summary": "Compared to ABBV, PFE's latest dividend declarations and earnings report reveal growth pressure, high payout ratios, and inventory buildup. Read the full analysis now.",
    "url": "https://finnhub.io/api/news?id=aee37e1c4747b96e5f5174d69ffbc8d59b02f1b22913d1a986cce509f9a8169e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762583923,
      "headline": "Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer",
      "id": 137377931,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161348037/image_2161348037.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Compared to ABBV, PFE's latest dividend declarations and earnings report reveal growth pressure, high payout ratios, and inventory buildup. Read the full analysis now.",
      "url": "https://finnhub.io/api/news?id=aee37e1c4747b96e5f5174d69ffbc8d59b02f1b22913d1a986cce509f9a8169e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and Metsera Reach Deal Expected to Top $10 Billion",
    "summary": "Pfizer  has agreed to buy the weight-loss drug startup  Metsera  in a deal that could be worth more than $10 billion, besting  Novo Nordisk  following a heated bidding war.  Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a share, Metsera said Friday.  In September, Pfizer had agreed to buy Metsera for up to $7.3 billion.",
    "url": "https://finnhub.io/api/news?id=c003326c1702b91d1b24d3db0aac8edf8e55cac083a10059294a8abfedf149c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762573800,
      "headline": "Pfizer and Metsera Reach Deal Expected to Top $10 Billion",
      "id": 137378432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer  has agreed to buy the weight-loss drug startup  Metsera  in a deal that could be worth more than $10 billion, besting  Novo Nordisk  following a heated bidding war.  Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a share, Metsera said Friday.  In September, Pfizer had agreed to buy Metsera for up to $7.3 billion.",
      "url": "https://finnhub.io/api/news?id=c003326c1702b91d1b24d3db0aac8edf8e55cac083a10059294a8abfedf149c7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer",
    "summary": "Metsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash.",
    "url": "https://finnhub.io/api/news?id=159b69355a04edadaafa1cf2976d6cb4b9378133bc6a053160ed95b1eb0f7422",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762569060,
      "headline": "Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer",
      "id": 137378433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash.",
      "url": "https://finnhub.io/api/news?id=159b69355a04edadaafa1cf2976d6cb4b9378133bc6a053160ed95b1eb0f7422"
    }
  }
]